journal article·2026-04

Long–term kinetic profiling of legumain–activated fluorescent probes and identification of a legumain substrate for cleavable linker design

Ly Thi Nguyen, Quynh Le Nhat, Hyun Bo Sim, Julie Kang, Nhan Nguyen Thanh, Ny Thi Tuong Le, Jong-Jin Kim, Dong-Jo Chang

Dyes and Pigments· Volume 247
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Biochemical and Structural Characterization · Protease and Inhibitor Mechanisms · Click Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (68)

Show source-provided references
1. Structure and function of legumain in health and disease10.1016/j.biochi.2015.09.022 ↗
2. The Mammalian cysteine protease legumain in health and disease10.3390/ijms232415983 ↗
3. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation10.1038/25379 ↗
4. Distinct protease requirements for antigen presentation in vitro and in vivo10.4049/jimmunol.0901486 ↗
5. Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone10.1016/S1074-7613(03)00085-2 ↗
6. Asparaginyl endopeptidase (Legumain) supports human Th1 induction via Cathepsin L-Mediated intracellular C3 activation10.3389/fimmu.2018.02449 ↗
7. Critical role for asparagine endopeptidase in endocytic toll-like receptor signaling in dendritic cells10.1016/j.immuni.2009.09.013 ↗
8. Vacuolar processing enzyme: an executor of plant cell death
9. Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase10.1016/j.molcel.2008.02.017 ↗
10. Legumain promotes tubular ferroptosis by facilitating chaperone-mediated autophagy of GPX4 in AKI10.1038/s41419-020-03362-4 ↗
11. Selective protein degradation through chaperone-mediated autophagy: implications for cellular homeostasis and disease10.3892/mmr.2024.13378 ↗
12. Mammalian legumain - a lysosomal cysteine protease with extracellular functions?10.1016/j.biochi.2019.06.002 ↗
13. Lysosomal proteases and their inhibitors10.3390/ijms251810070 ↗
14. An overview of targeting legumain for inhibiting cancers10.2174/1381612826666201125111625 ↗
15. Role of LGMN in tumor development and its progression and connection with the tumor microenvironment10.3389/fmolb.2023.1121964 ↗
16. The asparaginyl endopeptidase legumain: an emerging therapeutic target and potential biomarker for Alzheimer's disease10.3390/ijms231810223 ↗
17. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease
18. Legumain is expressed on macrophages in active demyelinating lesions of multiple sclerosis10.1111/cen3.12208 ↗
19. Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis10.1038/s41598-021-86191-5 ↗
20. Legumain is a paracrine regulator of osteoblast differentiation and mediates the inhibitory effect of TGF-beta 1 on osteoblast maturation10.3389/fendo.2024.1445049 ↗
21. Legumain regulates differentiation fate of human bone marrow stromal cells and is altered in postmenopausal osteoporosis10.1016/j.stemcr.2017.01.003 ↗
22. Legumain expression as a prognostic factor in breast cancer patients10.1007/s10549-006-9311-z ↗
23. Legumain protein as a potential predictive biomarker for Asian patients with breast carcinoma10.7314/APJCP.2014.15.24.10773 ↗
24. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment10.1038/ncomms5280 ↗
25. Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma10.1093/jnci/djz155 ↗
26. The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma10.1016/j.canlet.2020.07.012 ↗
27. High expression of the cysteine proteinase legumain in colorectal cancer–implications for therapeutic targeting10.1016/j.ejca.2014.10.020 ↗
28. The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer10.1080/15384047.2017.1294290 ↗
29. The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration10.1007/s13402-019-00486-4 ↗
30. Knockdown of legumain suppresses cervical cancer cell migration and invasion10.3727/096504015X14410238486649 ↗
31. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis10.1007/s00262-007-0389-x ↗
32. Blockade of asparagine endopeptidase inhibits cancer metastasis10.1021/acs.jmedchem.7b00228 ↗
33. Cancer cell secreted legumain promotes gastric cancer resistance to Anti-PD-1 immunotherapy by enhancing macrophage M2 polarization10.3390/ph17070951 ↗
34. Targeting legumain-mediated cell-cell interaction sensitizes glioblastoma to immunotherapy in preclinical models10.1172/JCI186034 ↗
35. Upregulation of LGMNP1 confers radiotherapy resistance in glioblastoma
36. Radiotherapy resistance driven by asparagine endopeptidase through ATR pathway modulation in breast cancer10.1186/s13046-025-03334-6 ↗
37. A protease-responsive fluorescent probe for sensitive imaging of legumain activity in living tumor cells10.1111/cbdd.13530 ↗
38. Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain10.1016/j.bmcl.2006.10.100 ↗
39. Design of a new peptide substrate probe of the putative biomarker legumain with potential application in prostate cancer diagnosis ex vivo10.1007/s10989-019-09994-1 ↗
40. Development of a smart activity-based probe to detect subcellular activity of asparaginyl endopeptidase in living cells10.1039/C7OB01467H ↗
41. Functional imaging of legumain in cancer using a new quenched activity-based probe10.1021/ja307083b ↗
42. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain10.1021/bc800448u ↗
43. Synthesis and evaluation of a CBZ-AAN-Dox prodrug and its in vitro effects on SiHa cervical cancer cells under hypoxic conditions10.1111/cbdd.12525 ↗
44. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy
45. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity10.1016/j.bmc.2014.04.056 ↗
46. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release10.1039/C9NR08558K ↗
47. The legumain protease-activated Auristatin prodrugs suppress tumor growth and metastasis without toxicity10.1002/cmdc.201000478 ↗
48. Legumain-cleavable 4-arm poly (ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release10.1016/j.actbio.2017.03.019 ↗
49. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated Auristatin prodrug10.1021/mp200434n ↗
50. Targeting legumain as a novel therapeutic strategy in cancers10.2174/1389450117666161216125344 ↗
51. Legumain/pH dual-responsive lytic peptide–paclitaxel conjugate for synergistic cancer therapy10.1080/10717544.2022.2081380 ↗
52. Antibody–Prodrug conjugates with KSP inhibitors and legumain‐mediated metabolite formation10.1002/chem.201900441 ↗
53. IL3RA-Targeting antibody–drug conjugate BAY-943 with a kinesin spindle protein inhibitor payload shows efficacy in preclinical models of hematologic malignancies10.3390/cancers12113464 ↗
54. Enzyme-agnostic lysosomal screen identifies new legumain-cleavable ADC linkers10.1021/acs.bioconjchem.1c00124 ↗
55. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers10.1080/00498254.2024.2352051 ↗
56. Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins10.1021/jm500544p ↗
57. Recent advances in the development of legumain-selective chemical probes and peptide prodrugs10.1515/hsz-2019-0135 ↗
58. Die kinetik der invertinwirkung
59. The origins of enzyme kinetics10.1016/j.febslet.2013.06.009 ↗
60. A guide to the Michaelis–Menten equation: steady state and beyond10.1111/febs.16124 ↗
61. Counter selection substrate library strategy for developing specific protease substrates and probes10.1016/j.chembiol.2016.05.020 ↗
62. Cloning, isolation, and characterization of Mammalian legumain, an asparaginyl endopeptidase10.1074/jbc.272.12.8090 ↗
63. Autocatalytic activation of human legumain at aspartic acid residues10.1016/S0014-5793(98)01281-2 ↗
64. Pig kidney legumain: an asparaginyl endopeptidase with restricted specificity10.1042/bj3390743 ↗
65. Substrate specificity of schistosome versus human legumain determined by P1-P3 peptide libraries10.1016/S0166-6851(02)00026-9 ↗
66. Characteristics of new bioreductive fluorescent probes based on the xanthene fluorophore: detection of nitroreductase and imaging of hypoxic cells10.1016/j.dyepig.2018.01.008 ↗
67. A fluorogenic assay: analysis of chemical modification of lysine and arginine to control proteolytic activity of trypsin10.3390/molecules26071975 ↗
68. A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine aminopeptidase10.1039/D2AN01145J ↗